Mayo Clinic Researchers Make Anti-Cancer Virus Discovery
Posted on: Tuesday, 1 August 2006, 21:00 CDT
Mayo Clinic researchers, working with colleagues in Germany, claim to have devised a multi-level safety feature for therapeutic viruses used to treat cancer.
In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells.
The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental - and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans, the researchers believe.
"Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explained Dr Roberto Cattaneo, lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells."
The researchers say their contribution is a key advance because it provides a method of designing a therapeutic virus that is safe, stable and that reliably targets and kills cancer cells. Importantly, it appears to greatly reduce the possibility that the virus would erroneously turn on and harm the patient by causing unintended infection.
As such, the Mayo innovation of the cancer-activated virus could represent a helpful safety advance for the promising experimental field of 'oncolytic virotherapy.'
Source: Datamonitor
Related Articles
- Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
- Journal Cover Shows Cell Infected By Virus First Viewed By MSU Scientists
- Virus Targets and Kills Apparent Cancer Stem Cells in Neuroblastoma
- New Report Examines Emerging Therapeutic, Diagnostic and Market Opportunities in the Area of Cancer Stem Cell Research
- Cancerous Stem Cells Researched
- South Texas Accelerated Research Therapeutics Gains Highly Respected Cancer Drug Researcher Michael Wick, Ph.D.
- Renowned Cancer Drug Researcher Chris Takimoto, M.D., Ph.D., Joins South Texas Accelerated Research Therapeutics
- Key Research on Cancer Stem Cells and Their Relevance and Impact on Drug and Diagnostic Discovery
- $20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
- OncoMed Pharmaceuticals Granted Fundamental Patent for Identifying Therapeutics Targeting Cancer Stem Cells
User Comments (0)

RSS Feeds